Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment-Reference-Cited by-同舟云学术

Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment

Published:2018-08-16 Issue:12 Volume:34 Page:2075-2088
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Chen Stephanie¹,Golam Sarowar²,Myers Julie³,Bly Chris³,Smolen Harry³,Xu Xiao¹

Affiliation:

1. AstraZeneca, Gaithersburg, MD, USA;

2. AstraZeneca, Gothenburg, Sweden;

3. Medical Decision Modeling Inc., Indianapolis, IN, USA

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2018.1505352

Reference212 articles.

1. Uncontrolled asthma: A review of the prevalence, disease burden and options for treatment

2. Eurostat. Respiratory disease statistics. Available at: http://ec.europa.eu/eurostat/statistics-explained/index.php/Respiratory_diseases_statistics [Last accessed January 2017]

3. National and regional asthma programmes in Europe

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Data on Tezepelumab in Patients With Severe Asthma in Germany;The Journal of Allergy and Clinical Immunology: In Practice;2024-09

2. Gaps in Care Among Uncontrolled Severe Asthma Patients in the United States;The Journal of Allergy and Clinical Immunology: In Practice;2024-07

3. The effect of targeted therapy on the quality of life of patients with polypous rhinosinusitis and comorbid bronchial asthma;Meditsinskiy sovet = Medical Council;2024-06-06

4. Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study;Advances in Therapy;2024-05-27

5. Biologic agents licensed for severe asthma: a systematic review and meta-analysis of randomised controlled trials;European Respiratory Review;2024-04-24